{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:34:21Z","timestamp":1776332061117,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.hlc.2009.11.002","type":"journal-article","created":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T04:23:55Z","timestamp":1265775835000},"page":"234-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serum Thromboxane B2 Compared to Five Other Platelet Function Tests for the Evaluation of Aspirin Effect in Stable Cardiovascular Disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Giselle","family":"Kidson-Gerber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalie","family":"Gemmell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananth M.","family":"Prasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beng Hock","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2009.11.002_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2009.11.002_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Aspirin Trialists\u2019 Collaboration","year":"1994","journal-title":"Br Med J"},{"key":"10.1016\/j.hlc.2009.11.002_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"Br Med J"},{"issue":"15","key":"10.1016\/j.hlc.2009.11.002_bib4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hlc.2009.11.002_bib5","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary heart disease","volume":"28","author":"Lordkipanidze","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2009.11.002_bib6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","article-title":"Dose- and time-dependent antiplatelet effects of aspirin","volume":"95","author":"Perneby","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hlc.2009.11.002_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1373\/clinchem.2006.081059","article-title":"Determination of aspirin responsiveness by use of whole blood platelet aggregometry","volume":"53","author":"Ivandic","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.hlc.2009.11.002_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000086690","article-title":"A critical appraisal of the phenomenon of aspirin resistance","volume":"104","author":"Poulsen","year":"2005","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.hlc.2009.11.002_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/107602960501100103","article-title":"Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggreagation methods","volume":"11","author":"Dyskiewicz-Korpanty","year":"2005","journal-title":"Clin Appl Thromb\/Hemost"},{"key":"10.1016\/j.hlc.2009.11.002_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.STR.0000151362.65339.f9","article-title":"Biological assessment of aspirin efficacy on healthy individuals: heterogenous response or aspirin failure?","volume":"36","author":"Gonzalez-Conejero","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.hlc.2009.11.002_bib11","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1538-7836.2006.01958.x","article-title":"Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signalling pathway(s) in cardiovascular events of aspirin-treated patients","volume":"4","author":"Ohmori","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.hlc.2009.11.002_bib12","first-page":"715","article-title":"Aspirin resistance in office patients treated for secondary stroke prophylaxis","volume":"37","author":"Gengo","year":"2006","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.hlc.2009.11.002_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.thromres.2007.04.010","article-title":"Screening for aspirin resistance in stable coronary artery patients by three different tests","volume":"121","author":"Chakroun","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.hlc.2009.11.002_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2009.11.002_bib15","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1161\/CIRCULATIONAHA.106.675587","article-title":"Evaluation of dose-related effects of aspirin on platelet function. Results from the Aspirin-Induced Platelet Effect (ASPECT) Study","volume":"115","author":"Gurbel","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2009.11.002_bib16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/01.STR.0000162719.11058.bd","article-title":"Screening for aspirin responsiveness after transient ischemic attack and stroke, comparison of 2 point-of-care platelet function tests with optical aggregometry","volume":"36","author":"Harrison","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.hlc.2009.11.002_bib17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/eurheartj\/ehm232","article-title":"Laboratory detection of \u2018aspirin resistance\u2019 what test should we use (if any)?","volume":"28","author":"Cattaneo","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2009.11.002_bib18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1161\/CIRCULATIONAHA.106.675991","article-title":"Variable platelet response to aspirin and clopidogrel in atherothrombotic disease","volume":"115","author":"Maree","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2009.11.002_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tvjl.2004.09.008","article-title":"Clopidogrel induced suppression of bovine platelet activation in vitro and a preliminary study of its effect on the development of Mannheimia haemolytica induced pneumonia","volume":"171","author":"Coomber","year":"2006","journal-title":"Vet J"},{"key":"10.1016\/j.hlc.2009.11.002_bib20","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2009.11.002_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/bmj.328.7430.30","article-title":"Omega 3 fatty acids and cardiovascular disease \u2013 fishing for a natural treatment","volume":"328","author":"Din","year":"2004","journal-title":"Br Med J"},{"issue":"7544","key":"10.1016\/j.hlc.2009.11.002_bib22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.38755.366331.2F","article-title":"Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review","volume":"332","author":"Hooper","year":"2006","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.hlc.2009.11.002_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1503\/cmaj.071654","article-title":"Should patients with cardiovascular disease take fish oil?","volume":"178","author":"Nair","year":"2008","journal-title":"Can Med Assoc J"},{"issue":"2","key":"10.1016\/j.hlc.2009.11.002_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/01.ATV.17.2.279","article-title":"Interactions between dietary fat, fish, fish oils and their effects on platelet function in men at risk of cardiovascular disease","volume":"17","author":"Mori","year":"1997","journal-title":"Arterioscl Thromb Vascul Biol"},{"issue":"3","key":"10.1016\/j.hlc.2009.11.002_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0049-3848(99)00103-6","article-title":"Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients","volume":"96","author":"Pirich","year":"1999","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.hlc.2009.11.002_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1054\/plef.2001.0275","article-title":"Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids","volume":"64","author":"Engstrom","year":"2001","journal-title":"Prostagland Leukot Essent Fatty Acids"},{"issue":"3","key":"10.1016\/j.hlc.2009.11.002_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890600640657","article-title":"Recent advances in antiplatelet therapy: the mechanisms, evidence and approach to the problems","volume":"38","author":"Horiuchi","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.hlc.2009.11.002_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2710.2001.00363.x","article-title":"Patient adherence to therapy: 3 decades of research","volume":"26","author":"Vermiere","year":"2001","journal-title":"J Clin Pharmacol Therap"},{"key":"10.1016\/j.hlc.2009.11.002_bib29","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2009.11.002_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH05-07-0516","article-title":"Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients","volume":"95","author":"Lepantalo","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hlc.2009.11.002_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jdiacomp.2007.05.002","article-title":"Aspirin resistance associated with HBA1c and obesity in diabetic patients","volume":"22","author":"Cohen","year":"2008","journal-title":"J Diab Comp"},{"key":"10.1016\/j.hlc.2009.11.002_bib32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ajh.20698","article-title":"Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chromic myeloproliferative disorders","volume":"81","author":"Manoharan","year":"2006","journal-title":"Am J Haematol"},{"issue":"3","key":"10.1016\/j.hlc.2009.11.002_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1373\/clinchem.2005.059535","article-title":"Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor","volume":"52","author":"Ivandic","year":"2006","journal-title":"Clin Chem"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950609011032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950609011032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:56:30Z","timestamp":1761414990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950609011032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1443950609011032"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2009.11.002","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Thromboxane B2 Compared to Five Other Platelet Function Tests for the Evaluation of Aspirin Effect in Stable Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2009.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2009 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}